Protein in the body can improve its ability to detect and treat viral infections such as influenza and hepatitis C. This conclusion leads a laboratory study by researchers from the University Institute of cancer in Pittsburgh, USA.
 
To start playback in the body, the virus actually "invaded" cells and "takes" control over them.
 
Experts explain that, despite progress in the field of vaccines and treatment diseases caused by viral infections remain among the leading causes of death in the world. According to them, there is a need for a new type of security and the new discovery appears to be promising for further studies.
 
Scientists isolated protein of similar oligoadenylate synthetase-occurring in humans, suffering from liver cancer, prichinen of hepatitis C. When the Expert increase the levels of this protein in human cells, observed inhibition of virus replication.
 
In later study found that murine organisms in which there is no presence of the protein are susceptible to a large extent of a viral infection, in comparison to those who have it.

Viruses affect the ribonucleic acid (RNA), including hepatitis C, influenza and respiratory syncytial virus, using RNA as the genetic material, when played back.
 
The types of treatment, based on the protein like oligoadenylate synthetase, can enhance the ability of cells to detect RNA, used by the virus, and thus to activate the immune system to stop its reproduction.

Medicament for the treatment of hepatitis C, developed by Gilead Sciences, received a positive evaluation by the Administration Food and Drug Administration in the U.S..
 
A positive response by the administration due to the success that the medicament is accomplished by treatment of the disease - more patients are cured in a shorter period of time compared with other drugs in the market.

Studies have shown that adding the drug to Sofosbuvir other prescribed medication is able to cure 90% of patients within 12 weeks, reports the Associated Press. So far no evidence of side effects associated with taking Sofosbuvir.
 
Since 1986 suffering from hepatitis C treated with interferon alpha protein. However, it is not suitable for everybody, and the positive outcome of the treatment was observed in less than half of the patients who take it.

On the other hand, side effects include depression, symptoms resemble those of the flu, such as fever, fatigue and headache. In some cases, they may even be exacerbated to the extent that may be necessary to slow or stop the treatment.

In 2011, the Administration has approved two drugs that can be used as an add-on to treat the most common type of hepatitis C. Studies have found that the drugs increase the number of patients cured by 65 - 75% of. Recently, however, pharmaceutical companies insist on medications that do not contain interferon.
 
Hepatitis C is a blood disorder that causes inflammation of the liver. Around 70-80% of people with hepatitis C do not notice any symptoms.

When they are present include: pain in the right upper abdomen, dark urine, fever, jaundice, nausea and vomiting. People with acute hepatitis C may develop a chronic infection.
 
Chronic hepatitis C can cause cirrhosis of the liver and is a leading factor in the development of liver cancer cherry.